Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Recent label updates for Bristol Myers’ Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could lead to greater categor ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Cytokinetics Inc. (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...